Rubin Lab


Crohn’s disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomized controlled trial.

Zisman-Ilani Y, Thompson KD, Siegel LS, Mackenzie T, Crate DJ, Korzenik JR, Melmed GY, Kozuch P, Sands BE, Rubin DTRegueiro MD, Cross R, Wolf DC, Hanson JS, Schwartz RM, Vrabie R, Kreines MD, Scherer T, Dubinsky MC, Siegel CA. Aliment Pharmacol Ther. 2022. [Epub ahead of print Nov 14 2022]. PMID: 36377259.

Treat-to-target and sequencing therapies in Crohn’s disease.

Garcia NM, Cohen NA, Rubin DT. United European Gastroenterol J. Epub 2022. PMID: 36507876.

Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation.

Scott FI, Ehrlich O, Wood D, Viator C, Rains C, DiMartino L, McArdle J, Adams G, Barkoff L, Caudle J, Cheng J, Kinnucan J, Persley K, Sariego J, Shah S, Heller C, Rubin DT. Inflamm Bowel Dis. 2022. [Epub head of print Oct 22 2022]. PMID: 36271884.

A Summary of the BRIDGe Summit on Damage-Related Progression of Ulcerative Colitis: Establishing Research Priorities.

Krugliak Cleveland N, Bressler B, Siegel CA, BRIDGe UC Progression Summit Collaborators. Gastroenterology. 2022; 163(6):1505-1509. PMID: 35964690.

Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes.

Cohen NA, Steinberg JM, Silfen A, Traboulsi C, Rodriguez TC, Singer JM, Patel S, Cohen RD, Dalal SR, Sakuraba A, Pekow J, Micic D, Rubin DT. Dig Dis Sci. 2022. [Epub ahead of print Oct 15 2022]. PMID: 36242686.

Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses.

Buie MJ, Quan J, Windsor JW, Coward S, Hansen TM, King JA, Kotze PG, Gearry RB, Ng SC, Mak JWY, Abreu MT, Rubin DT, Bernstein CN, Banerjee R, Yamamoto-Furusho JK, Panaccione R, Seow CH, Ma C, Underwood FE, Ahuja V, Panaccione N, Shaheen AA, Holroyd-Leduc J, Kaplan GG, on behalf of the Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group: Balderramo D, Chong VH, Juliao-Baños F, Dutta U, Simadibrata M, Kaibullayeva J, Sun Y, Hilmi I, Ali RAR, Paudel MS, Altuwaijri M, Hartono JL, Wei SC, Limsrivilai J, El Ouali S, Vergara BI, Dao VH, Kelly P, Hodges P, Miao Y, Li M. Clin Gastroenterol Hepatol. 2022. [Epub ahead of print Jul 19 2022]. PMID: 35863682.

Health-related quality of life outcomes with tofacitinib treatment in patients with ulcerative colitis in the open-label extension study, OCTAVE Open.

Biedermann L, Dubinsky MC, Vermeire S, Fellmann M, Gardiner S, Hur P, Mundayat R, Panes J, Rubin DT. Inflamm Bowel Dis. 2022. [Epub ahead of print Oct 15 2022]. PMID: 36242764.

Efficacy and Safety of Ivarmacitinib in Patients with Moderateto-Severe, Active, Ulcerative Colitis: A Phase II Study​.

Chen B, Zhong J, Li X, Pan F, Ding Y, Zhang Y, Chen H, Liu F, Zhang Z, Zhang L, Drozda R, Oliinyk O, Goh AH, Chen X, Sun X, Rubin DT, Sandborn WJ, Chen M. Gastroenterology. 2022;163(6):1555-1568. PMID: 35963369.

Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Olivera PA, Lasa JS, Zubiaurre I, Jairath V, Abreu MT, Rubin DT, Reinisch W, Magro F, Rahier JF, Danese S, Rabaud C, Peyrin-Biroulet L. J Crohns Colitis. 2022. [Epub ahead of print Sep 10 2022]. PMID: 36087107.

Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis.

Yuan W, Marwaha JS, Rakowsky ST, Palmer NP, Kohane IS, Rubin DT, Brat GA, Feuerstein JD. Inflamm Bowel Dis. 2022. [Epub ahead of print Jul 4 2022]. PMID: 35786768.